CAS: 2356-16-3; Triethyl 2-Fluoro-2-Phosphonoacetate

该化合物是一种有机磷化合物,其特征是磷功能组的特征是磷化物,这种化合物一般是无色的,淡黄色的液体,以相对低的挥发性闻名,其特征是三乙基酯酸,它有助于有机溶剂中的溶解性,同时在水中不易溶解;氟原子的存在会增强它的再活动,并可能影响其生物活动,使其在各种化学应用中具有兴趣,包括作为有机合成和农用化学开发中的潜在中间体.三乙基-2-氟-2-磷酸酯可能会表现出磷酸的典型特性,例如某些酶的潜在抑制剂,这在生物化学研究中可能具有相关性.由于其化学结构,它也可能参与核分裂性替代反应.与许多有机磷化合物一样,在处理该物质时应采取安全防范措施,因为它可能构成健康风险.

结构式图片

相似化合物

30094-32-7 7071-12-7 124755-24-4

欧盟法规

ECHA物质C&L通报

上下游产品

CAS号401-55-8 溴氟乙酸乙酯 | CAS号122-52-1 亚磷酸三乙酯 | CAS号867-13-0 磷酰基乙酸三乙酯 | CAS号401-58-1 氟碘乙酸乙酯 | CAS号65094-25-9 DIETHYL (DIBROM... | CAS号7071-02-5 potassium salt ... | CAS号401-56-9 氯氟乙酸乙酯 | CAS号762-04-9 亚磷酸二乙酯 | CAS号541-41-3 氯甲酸乙酯 | CAS号2284-70-0 2-Butenoicacid,... | CAS号547-63-7 异丁酸甲酯 | CAS号26928-12-1 2-fluoro-3-(4-m... | CAS号30094-32-7 2-(二乙氧基磷酰基)-2-氟乙酸 | CAS号101560-16-1 ethyl 2-fluoro-... | CAS号113307-25-8 ethyl 2-cyclope... | CAS号20397-61-9 (Z)-Alpha-氟肉桂酸 | CAS号1479-22-7 2-氟-3-氧代-3-苯丙酸乙酯 | CAS号760-80-5 2-氟代丙烯酸乙酯

合成工艺路线路线简述

  • 合成目标产物 Triethyl 2-Fluoro-2-Phosphonoacetate 主要起始原料 Ethyl Bromofluoroacetate And Triethyl Phosphate
  • (文献来源)合成步骤主要原料 Ethyl Bromofluoroacetate 和 Triethyl Phosphate
二乙基[二溴(氟)甲基]膦酸酯置于盐酸,正丁基锂,乙醇,水体系中,用 四氢呋喃,正己烷,二氯甲烷 用作溶剂,化学反应生成2-氟-2-磷酰基乙酸三乙酯
参考文献:Preparation Of Triethyl 2-Fluoro-2-Phosphonoacetate
标题:Preparation Of Triethyl 2-Fluoro-2-Phosphonoacetate
摘要:Triethyl 2-Fluoro-2-Phosphonoacetate Was Prepared In One Step From Dibromofluoromethylphosphonate And Ethyl Chloroformate.
Doi:10.1080/00397919408011733

海关参考信息

专利信息


专利号:WO-0200681-A1
优先权日:2000-06-27
标题 :20-fluoro-17(20)-vinyl steroids as inhibitors of c17-20-lyase and 5-alpha reductase
发明人:PEET NORTON P; WEINTRAUB PHILIP M; BURKHART JOSEPH P; GATES CYNTHIA A
权利人:AVENTIS PHARMA INC; PEET NORTON P; WEINTRAUB PHILIP M; BURKHART JOSEPH P; GATES CYNTHIA A
摘要:The invention related to 20κ-fluoropregna-4,17(20)-dien-3-on-21-oic acid ethyl ester, 20κ-fluoro-3β-hydroxypregna-4,17(20)-dien-21-oic acid ethyl ester, 20κ-fluoro-21-hydroxypregna-4,17(20)-dien-3-one, 20κ-fluoropregna-4,17(20)-dien-3β,21-diol and related compounds and to compositions incorporating these compounds, as well as the inhibition of C17,20 lyase, 5α-reductase and C17-hydroxylase, and to the use of these compounds in the treatment of androgen and estrogen mediated or dependent disorders, including benign prostatic hyperplasia, prostate cancer, breast cancer and DHT-mediated disorders such as acne and hirsutism. Treatment of disorders related to the over synthesis of cortisol, for example, Cushing's Syndrome are also included. The treatment of androgen-dependent disorders also includes a combination therapy with known androgen-receptor antagonists, such as flutamide. The compounds of the invention have general formulae (I).

专利号:US-11046648-B2
优先权日:2017-03-01
标 题 :Transition metal-catalyzed protodecarboxylation of α-halo-acrylic acid derivatives
发明人:DANG MAI THI QUYNH; HAMPEL THOMAS ARMIN; KOCH SANDRA; NORDSTROM FREDRIK LARS; REEVES JONATHAN TIMOTHY; REICHEL CARSTEN; SCHOERER MARVIN; STANGE CHRISTIAN; VOLCHKOV IVAN N; ZHONG LI; ZIMMERMANN UWE JOHANNES
权利人:BOEHRINGER INGELHEIM INT
摘要:The present invention relates to a method for the synthesis of a halo olefin of formula (I)wherein Hal, R1, R2, R3, R4, X and Y are as defined herein, or a salt thereof.

专利号:US-4808749-A
优先权日:1980-10-01
标 题:Cyclopropane carboxylic esters and acids
发明人:MARTEL JACQUES; TESSIER JEAN; TECHE ANDRE
权利人:ROUSSEL UCLAF
摘要:Novel esters in all possible isomeric forms of the formula ##STR1## wherein R is selected from the group consisting of (a) optionally unsaturated alkyl of 1 to 8 carbon atoms and optionally unsaturated cycloalkyl or cycloalkyl-alkyl of 3 to 8 carbon atoms optionally substituted with at least one member of the group consisting of halogen, --OH, --SH, --OR', --SR', --NO 2 , ##STR2## --CN, --SO 3 H, --PO 4 H 2 , ##STR3## --SO 2 AlK 2 , --SO 3 AlK 3 , aryl optionally substituted with at least one member of the group consisting of --OH, alkoxy of 1 to 8 carbon atoms, alkyl of 1 to 8 carbon atoms, halogen, --CF 3 , --OCF 3 , --SCF 3 and ##STR4## R' is alkyl of 1 to 8 carbon atoms, R' and R'' are individually selected from the group consisting of hydrogen and alkyl of 1 to 8 carbon atoms, AlK 1 , AlK 2 and AlK 3 are individually alkyl of 1 to 18 carbon atoms, (b) aryl of 6 to 14 carbon atoms optionally substituted with at least one substitutent selected from the group consisting of --OH, alkoxy of 1 to 8 carbon atoms, alkyl of 1 to 8 carbon atoms, halogen, --OCF 3 , --CF 3 and --SCF 3 and (c) heterocycle optionally substituted with at least one member of the group consisting of --OH, alkoxy of 1 to 8 carbon atoms, alkyl of 1 to 8 carbon atoms, halogen, --CF 3 , --OCF 3 and --SCF 3 , B is selected from the group consisting of optionally unsaturated alkyl of 1 to 18 carbon atoms, optionally unsaturated cycloalkyl of 3 to 18 carbon atoms and the remainder of an alcohol used in synthesis of pyrethrinoid esters, X is halogen and the ethylenic double bond may have Z or E geometry having parasitic activity, especially insecticidal acaricidal and nematocidal activity.

专利号:US-6413951-B2
优先权日:2000-06-27
标题:20-fluoro-17(20)-vinyl steroids
发明人:PEET NORTON P; WEINTRAUB PHILIP M; BURKHART JOSEPH P; GATES CYNTHIA A
权利人:AVENTIS PHARMA INC
摘要:The invention relates to 20ξ-fluoropregna-4,17(20)-dien-3-on-21-oic acid ethyl ester, 20ξ-fluoro-3beta-hydroxypregna-5,17(20)-dien-21-oic acid ethyl ester, 20ξ-fluoro-21-hydroxypregna-4,17 (20)-dien-3-one, 20ξ-fluoropregna-5,17(20)-dien-3beta,21-diol and related compounds and to compositions incorporating these compounds, as well as the inhibition of C17,20 lyase, 5alpha-reductase and C17-hydroxylase, and to the use of these compounds in the treatment of androgen and estrogen mediated or dependent disorders, including benign prostatic hyperplasia, prostate cancer, breast cancer and DHT-mediated disorders such as acne and hirsutism. Treatment of disorders related to the over synthesis of cortisol, for example, Cushing's Syndrome are also included. The treatment of androgen-dependent disorders also includes a combination therapy with known androgen-receptor antagonists, such as flutamide. The compounds of the invention have the following general formulae:

专利号:US-5856530-A
优先权日:1996-05-14
标题:Antipicornaviral compounds and methods for their use and preparation
发明人:WEBBER STEPHEN E; DRAGOVICH PETER S; PRINS THOMAS J; REICH SIEGFRIED H; LITTLE JR THOMAS L; LITTLEFIELD ETHEL S; MARAKOVITS JOSEPH T; BABINE ROBERT E; BLECKMAN TED M
权利人:AGOURON PHARMA
摘要:Picornaviral 3C protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of picornaviral 3C proteases. These compounds, as well as pharmaceutical compositions that contain these compounds, are suitable for treating patients or hosts infected with one or more picornaviruses. Several novel methods and intermediates can be used to prepare the novel picornaviral 3C protease inhibitors of the present invention.

专利号:US-6362166-B1
优先权日:1996-05-14
标 题 :Antipicornaviral compounds and methods for their use and preparation
发明人:WEBBER STEPHEN E; DRAGOVICH PETER S; PRINS THOMAS J; REICH SIEGFRIED H; LITTLE JR THOMAS L; LITTLEFIELD ETHEL S; MARAKOVITS JOSEPH T; BABINE ROBERT E; BLECKMAN TED M
权利人:AGOURON PHARMA
摘要:Picornaviral 3C protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of picornaviral 3C proteases. These compounds, as well as pharmaceutical compositions that contain these compounds, are suitable for treating patients or hosts infected with one or more picornaviruses. Several novel methods and intermediates can be used to prepare the novel picornaviral 3C protease inhibitors of the present invention.
常州环灵化工有限公司
⚠️ 未注册 · 未认证企业
⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
数据来源于公开网络搜索,平台未作核实,请自行辨别。
🏢敬请 企业认领
🏬开设公司展台
📢获取免费会员权益
🎖️点亮专属注册企业标签
📇展现公司完整信息 样本查看立即注册认领 →
网址: http://www.huanlingchem.com
电话: 0519-89803565 13776850645👤
📞常州环灵化工有限公司 ⚠️参考联系方式

销售电话:0519-89803565 13776850645
邮箱:info4@huanlingchem.com
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

⚠️ 未注册 · 未认证企业
注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
上海氟锐医药科技有限公司
⚠️ 未注册 · 未认证企业
⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
数据来源于公开网络搜索,平台未作核实,请自行辨别。
🏢敬请 企业认领
🏬开设公司展台
📢获取免费会员权益
🎖️点亮专属注册企业标签
📇展现公司完整信息 样本查看立即注册认领 →
网址: http://www.fluororing.com
企业联系电话:021-37787203;18018698069👤
📞上海氟锐医药科技有限公司 ⚠️参考联系方式
联系人:金经理
电话:021-37787203;18018698069
手机:18018698069
传真:QQ:3917053946;laurajin@fluororing.com
邮箱:sales@fluororing.com
通信地址: 上海车墩镇车新公路185号4幢2层202室
邮编:
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

地址:上海车墩镇车新公路185号4幢2层202室
⚠️ 未注册 · 未认证企业
注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
第 1 / 1 页
现货

供应商参考报价(招募中)

品牌试剂参考报价(招募中)

📌 第三方产品分析报告

✅ COA系统入驻 | 共享模式

主要参考文献

[参考文献]: P W Collins, Et Al. Synthesis And Gastrointestinal Pharmacology Of The 4-Fluoro Analogue Of Enisoprost. J Med Chem. 1987 Nov;30(11):1952-5.

合成参考文献


摘要:Couve-Bonnaire, S.; Castanheiro, T.; Bouillon, J.-P., Science of Synthesis: Modern Strategies in Organofluorine Chemistry, (2025) 2.
📝 需求与反馈
尽可能描述清楚需求与问题信息
×

通知